Labetuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Labetuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetcarcinoembryonic antigen
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
 ☒N☑Y (what is this?)  (verify)

Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2]

Also tried in patients with MTC (medullary thyroid carcinoma)

This drug was developed by Immunomedics, Inc.

References[edit]